104 related articles for article (PubMed ID: 31120283)
1. Behavioral effects of chronic WIN 55,212-2 administration during adolescence and adulthood in mice.
Johnson KR; Boomhower SR; Newland MC
Exp Clin Psychopharmacol; 2019 Aug; 27(4):348-358. PubMed ID: 31120283
[TBL] [Abstract][Full Text] [Related]
2. Effects of chronic cannabinoid exposure during adolescence on reward preference and mPFC activation in adulthood.
Jacobs-Brichford E; Manson KF; Roitman JD
Physiol Behav; 2019 Feb; 199():395-404. PubMed ID: 30529340
[TBL] [Abstract][Full Text] [Related]
3. Inverse relationship of cannabimimetic (R+)WIN 55, 212 on behavior and seizure threshold during the juvenile period.
Rudenko V; Rafiuddin A; Leheste JR; Friedman LK
Pharmacol Biochem Behav; 2012 Jan; 100(3):474-84. PubMed ID: 22019959
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia.
Gleason KA; Birnbaum SG; Shukla A; Ghose S
Transl Psychiatry; 2012 Nov; 2(11):e199. PubMed ID: 23188199
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid exposure in pubertal rats increases spontaneous ethanol consumption and NMDA receptor associated protein levels.
Klugmann M; Klippenstein V; Leweke FM; Spanagel R; Schneider M
Int J Neuropsychopharmacol; 2011 May; 14(4):505-17. PubMed ID: 21211107
[TBL] [Abstract][Full Text] [Related]
6. Chronic exposure to cannabinoids during adolescence causes long-lasting behavioral deficits in adult mice.
Tomas-Roig J; Benito E; Agis-Balboa RC; Piscitelli F; Hoyer-Fender S; Di Marzo V; Havemann-Reinecke U
Addict Biol; 2017 Nov; 22(6):1778-1789. PubMed ID: 27578457
[TBL] [Abstract][Full Text] [Related]
7. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.
Bilir KA; Anli G; Ozkan E; Gunduz O; Ulugol A
Clin Exp Dermatol; 2018 Jul; 43(5):553-558. PubMed ID: 29424035
[TBL] [Abstract][Full Text] [Related]
8. Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes.
Vera G; López-Miranda V; Herradón E; Martín MI; Abalo R
Pharmacol Biochem Behav; 2012 Aug; 102(2):335-43. PubMed ID: 22609797
[TBL] [Abstract][Full Text] [Related]
9. Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55,212-2.
Schneider M; Drews E; Koch M
Behav Pharmacol; 2005 Sep; 16(5-6):447-54. PubMed ID: 16148450
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoids reverse the effects of early stress on neurocognitive performance in adulthood.
Alteba S; Korem N; Akirav I
Learn Mem; 2016 Jul; 23(7):349-58. PubMed ID: 27317195
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.
Castelli MP; Paola Piras A; D'Agostino A; Pibiri F; Perra S; Gessa GL; Maccarrone M; Pistis M
Eur J Pharmacol; 2007 Nov; 573(1-3):11-9. PubMed ID: 17644084
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia–reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS.
González C; Herradón E; Abalo R; Vera G; Pérez-Nievas BG; Leza JC; Martín MI; López-Miranda V
Diabetes Metab Res Rev; 2011 May; 27(4):331-40. PubMed ID: 21309057
[TBL] [Abstract][Full Text] [Related]
13. Adolescent Exposure to the Synthetic Cannabinoid WIN 55212-2 Modifies Cocaine Withdrawal Symptoms in Adult Mice.
Aguilar MA; Ledesma JC; Rodríguez-Arias M; Penalva C; Manzanedo C; Miñarro J; Arenas MC
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635664
[TBL] [Abstract][Full Text] [Related]
14. Exposure to cannabinoid agonist WIN 55,212-2 during early adolescence increases alcohol preference and anxiety in CD1 mice.
Frontera JL; Gonzalez Pini VM; Messore FL; Brusco A
Neuropharmacology; 2018 Jul; 137():268-274. PubMed ID: 29778010
[TBL] [Abstract][Full Text] [Related]
15. Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer.
Greish K; Mathur A; Al Zahrani R; Elkaissi S; Al Jishi M; Nazzal O; Taha S; Pittalà V; Taurin S
J Control Release; 2018 Dec; 291():184-195. PubMed ID: 30367922
[TBL] [Abstract][Full Text] [Related]
16. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
17. Effects of prenatal exposure to the CB-1 receptor agonist WIN 55212-2 or CO on the GABAergic neuronal systems of rat cerebellar cortex.
Benagiano V; Lorusso L; Flace P; Girolamo F; Rizzi A; Sabatini R; Auteri P; Bosco L; Cagiano R; Ambrosi G
Neuroscience; 2007 Nov; 149(3):592-601. PubMed ID: 17916407
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia.
Martínez-Orgado J; Fernández-Frutos B; González R; Romero E; Urigüen L; Romero J; Viveros MP
Brain Res Mol Brain Res; 2003 Jun; 114(2):132-9. PubMed ID: 12829323
[TBL] [Abstract][Full Text] [Related]
19. Subchronic cannabinoid agonist (WIN 55,212-2) treatment during cocaine abstinence alters subsequent cocaine seeking behavior.
González-Cuevas G; Aujla H; Martin-Fardon R; López-Moreno JA; Navarro M; Weiss F
Neuropsychopharmacology; 2007 Nov; 32(11):2260-6. PubMed ID: 17392740
[TBL] [Abstract][Full Text] [Related]
20. Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55,212-2.
Pandolfo P; Pamplona FA; Prediger RD; Takahashi RN
Eur J Pharmacol; 2007 Jun; 563(1-3):141-8. PubMed ID: 17374533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
